Cardio-vascular
Refine Search
Biotechnology
UK-based Ashington Innovation has agreed to acquire in Cell Therapy Limited in a £135 million ($172 million) reverse takeover, resulting in its own shares being suspended from trading in London. 17 August 2023
Biotechnology
US biotech Cytokinetics is seeking to develop medicines that treat cardiovascular and neuromuscular diseases of impaired muscle function. 15 August 2023
Generics
US pharma giant Pfizer and the Scripps Research Institute have accused generics company Dexcel Pharma Technologies of patent infringement. 14 August 2023
Pharmaceutical
UK-based specialty pharmaceutical company CNX Therapeutics today announced it has successfully completed the acquisition of four cancer support products from Clinigen, a global pharmaceutical services company. 11 August 2023
Biotechnology
San Diego, USA-based next generation RNA therapeutics company ADARx Pharmaceuticals today revealed it has closed an oversubscribed Series C financing of $200 million. 9 August 2023
Pharmaceutical
Germany’s Bayer might have a new chief executive in Bill Anderson, but many of the challenges faced by his predecessor Werner Baumann remain. 8 August 2023
Pharmaceutical
Shares in Danish diabetes giant Novo Nordisk have risen sharply after positive top-line data were announced from the SELECT cardiovascular outcomes trial. 8 August 2023
Biotechnology
The dyslipidemia market will be driven by the launch of therapies with promising efficacies and new mechanism of actions, as well as the growth of the dyslipidemia population. 8 August 2023
Biotechnology
Privately-held UK biotech Evox Therapeutics has announced a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, USA. 4 August 2023
Biotechnology
Last week’s deal-making news featured Swiss pharma giant Roche announcing a licensing agreement for Alnylam’s hypertension candidate zilebesiran that could earn the US biotech as much as $2.8billion. US biotech Biogen released second-quarter 2023 financial results along with a cost-saving plans and prospects for the new fully-approved Alzheimer’s disease drug Leqembi, developed and marketed with Japan’s Eisai. Eli Lilly released further encouraging Phase III data for its candidate tirzepatide in weight loss. The drug is already marketed under the trade name Mounjaro for diabetes. Also. On Friday, Biogen entered into an agreement to acquire Reata Pharma, and its newly-approved rare disease drug Skyclarys, for $7.3 billion. 30 July 2023
Biotechnology
Shares in BioCardia, a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, closed nearly 50% lower on Monday. 25 July 2023
Biotechnology
Swiss pharma giant Roche has entered into a new partnership with USA-based Alnylam to develop and commercialize zilebesiran, the latter’s investigational RNAi therapeutic currently in Phase II for the treatment of hypertension. 24 July 2023
Biotechnology
Research news last week included Eli Lilly announcing a major breakthrough in Alzheimer’s disease (AD) with its candidate donanemab at the Alzheimer’s Association International Conference (AAIC). BridgeBio revealed positive Phase III data on its acoramidis in the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Also, the USA’s Vir Biotechnologies released disappointing Phase II trial results for its seasonal influenza A prevention candidate VIR-2482. On the deal making front, US genetics firm Scribe Therapeutics expanded its collaboration with France’s Sanofi in a deal worth a potential $1.2 billion, for gene editing in sickle cell disease. 23 July 2023
Pharmaceutical
Shares in Novartis closed 5% higher on Tuesday after the Swiss pharma major announced its second-quarter 2023 financial results and other updates for shareholders. 18 July 2023
Pharmaceutical
BridgeBio Pharma saw its shares rocket 66% to $30.30 pre-market as it released long anticipated trial results for its acoramidis. 17 July 2023
Pharmaceutical
As patents expire and low-cost generics enter the sector, the atrial fibrillation (AF) market is forecast to decline at a compound annual growth rate (CAGR) of 1.3% from $14.53 billion in 2022 to $12.8 billion in 2032 across the eight major markets (8MM: USA, 5EU (France, Germany, Italy, Spain, and the UK), Canada, and Japan). 17 July 2023
Generics
Global drugmakers continue to defend the rights for their original drugs in Russia by participating in legal disputes with local generics’ producers, The Pharma Letter’s local correspondent reports. 12 July 2023
Pharmaceutical
Swiss pharma giant Novartis yesterday announced that the US District Court for the District of Delaware issued a negative decision regarding the validity of a patent covering its heart failure treatment Entresto and combinations of sacubitril and valsartan, which expires in 2025 with its pediatric exclusivity. 8 July 2023
Pharmaceutical
Bristol Myers Squibb has announced that the European Commission (EC) has approved Camzyos (mavacamten) to treat symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (HCM). 27 June 2023
Biotechnology
Shares of US cell therapy developer Talaris Therapeutics leapt 26% to $2.77 this morning, as the company announced a proposed reverse merger. 22 June 2023
Biotechnology
Dutch clinical-stage biotech NewAmsterdam Pharma, which is focused on non-statin medicines for patients at risk of cardiovascular disease (CVD), has announced positive top-line data from its Phase III TANDEM clinical trial. 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Anthos Therapeutics has presented data at the American Heart Association (AHA) Scientific Sessions from its landmark AZALEA-TIMI 71 study showing that abelacimab led to consistent and substantial reductions in bleeding for patients on or off antiplatelet (APT) therapy, compared to rivaroxaban. 18 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted medicine for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older, under development by Ionis Pharmaceuticals. 4 November 2024
Biotechnology
Ascendis Pharma has granted fellow Denmark-based Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases. 4 November 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Pharmaceutical
Denmark-based Novo Nordisk’s oral semaglutide, marketed as Rybelsus for type 2 diabetes, has not gained much presence in the GLP-1 receptor agonists (GLP-1RAs) market despite its approval in 2019, as its injectable alternatives prove to have higher efficacy and results both in diabetes and obesity patients. 28 October 2024
Pharmaceutical
Germany’s Bayer has entered into an exclusive licensing agreement with privately-held Dewpoint Therapeutics for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. 25 October 2024
Pharmaceutical
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Pharmaceutical
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Generics
Lexicon Pharmaceuticals announced that Viatris has obtained an exclusive license from Lexicon to commercialize sotagliflozin outside of the USA and Europe in all indications. 18 October 2024
Pharmaceutical
Johnson & Johnson has reported revenue of $22.5 billion for the third quarter of 2024, a 5.2% increase year-over-year. 15 October 2024
Generics
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Pharmaceutical
Cardiopulmonary diseases specialist Liquidia Corporation closed Monday’s trading 11% higher following a favorable court ruling. 8 October 2024
Pharmaceutical
AstraZeneca has entered into an exclusive license agreement with China’s CSPC Pharmaceutical to advance the development of an early stage, novel small molecule lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidemia. 7 October 2024
Pharmaceutical
Privately-held metabolic health specialist Rivus Pharmaceuticals has announced new clinical data from the Phase IIa HuMAIN study of HU6 in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) 1 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze